Evidence map›Paper›PMID 39942636›Full record

ArticleMolecules (Basel, Switzerland)2025

Affinity Maturation for Antibody Engineering: The Critical Role of Residues on CDR Loops of Antibodies in Antigen Binding.

Mutsumi Yoshida, Masayuki Oda

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mutsumi YoshidaGraduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto 606-8522, Japan.
Masayuki OdaGraduate School of Life and Environmental Sciences, Kyoto Prefectural University, 1-5 Hangi-cho, Shimogamo, Sakyo-ku, Kyoto 606-8522, Japan.ORCID 0000-0002-8568-4223

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During the course of affinity maturation, antibodies exhibit enhanced antigen-binding affinities by altering the amino acids in their variable regions. Understanding the structural basis of these antibodies can be beneficial for antibody engineering. We determined the crystal structures of single-chain Fv (scFv) antibodies against (4-hydroxy-3-nitrophenyl)acetyl, C6 and E11, which had undergone affinity maturation. Compared with germline-type antibodies, the affinity-matured antibodies with somatic hypermutation from Lys58 to Arg58 of the heavy chain located in the complementarity-determining region 2 (CDR2) seemed to be critical for increasing the antigen-binding affinity. E11 possessed a disulfide bond at the base of CDR3 in the heavy chain, which contributed to a further increase in its antigen-binding affinity compared with that of C6. In this study, we generated several mutant scFvs of C6 and E11 and analyzed their antigen-binding thermodynamics using isothermal titration calorimetry. The results indicated that the CDR conformations could adjust antigen-binding not only at the mutated sites but also at the surrounding residues. The analysis of folding thermodynamics showed that the stability of the affinity-matured antibodies was lower than that of the germline-type antibodies and remarkably increased upon strong antigen binding. The results also indicated that the structural dynamics of the affinity-matured antibodies were greater than those of the germline-type antibodies and decreased upon antigen binding.

Indexed as

Antibody AffinityAntigensComplementarity Determining RegionsProtein EngineeringSingle-Chain AntibodiesHumansModels, MolecularProtein BindingProtein ConformationThermodynamicsAntigensComplementarity Determining RegionsSingle-Chain Antibodiesaffinity maturationantigen bindingcrystal structurethermal stability

Identifiers

PMID39942636
PMCPMC11819675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.